For immediate release
Chicago, IL – July 12, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), The Walt Disney Co. DIS, CVS Health Corp. CVS, Citigroup Inc. C and Canadian National Railway Co. CNI.
Here are the highlights from Monday’s analyst blog:
Top research reports for Berkshire Hathaway, Walt Disney and CVS
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., The Walt Disney Co. and CVS Health Corp. These research reports have been handpicked from over 70 reports released by our analyst team today.
You can see all research reports from today here >>>
Berkshire Hathaway shares have outperformed the Zacks Insurance – P&C industry over the past year (+0.3% vs. -5.0%). The Zacks analyst believes Berkshire’s inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings accretive top-up buybacks and indicates the company’s financial flexibility. Continued growth in the insurance business is fueling free float growth, driving earnings and generating maximum return on equity. The non-insurance business is performing better with increased revenues in recent years. A strong level of capital provides further momentum.
However, exposure to catastrophe losses induces earnings volatility and also affects Berkshire’s P&C underwriting results. Huge capital expenditures remain a headwind for the company.
(You can read the full Berkshire Hathaway research report here >>>)
waltz disney shares were down -38.1% year-to-date against media conglomerate Zacks’ industry decline of -32.0%. The Zacks analyst believes Disney+’s profitability is expected to be negatively impacted by higher content investments, which will lead to higher programming and production costs at Media and Entertainment Distribution. The closure of its Asian theme park due to COVID-19 does not bode well for growth in parks, experiences and product revenue.
Still, the company is benefiting from the growing popularity of Disney+, thanks to a strong content portfolio and a cheaper bundle. Availability in Nordic countries, Latin America and other Asian territories helps it expand its user base. The revival of the Parks activity is also promising in the long term.
(You can read the full research report on Walt Disney here >>>)
SVC Health shares have outperformed industry Zacks Retail – Pharmacies and Drug Stores over the past year (+17.7% vs. +4.9%). The Zacks analyst believes the company’s continued investments to address housing insecurities and improve access to health services in underserved communities appear encouraging.
Rising earnings per share (EPS) forecasts for 2022 give cause for optimism. In fact, CVS Health ended the first quarter of 2022 with earnings and revenue exceeding the Zacks consensus estimate.
Still, shrinking margins on escalating costs don’t bode well. Declining operating income due to ongoing litigation with the State of Florida to settle all opioid claims against CVS Health is causing apprehension.
(You can read the full CVS research report here >>>)
Other noteworthy reports we are presenting today include Citigroup Inc. and Canadian National Railway Company.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.
See Free Stocks >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
Zacks names ‘only one best choice for doubling up’
From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.
It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.
This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.
Free: See our best stock and our 4 finalists >>
Click to get this free report
Citigroup Inc. (C): Free Stock Analysis Report
Canadian National Railway Company (CNI): Free Inventory Analysis Report
Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
The Walt Disney Company (DIS): Free Inventory Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.